Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
507 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Epithelial Ovarian Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape. Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, pain in the pelvis and gastrointestinal problems, such as gas, bloating, or constipation. There are different types of treatment for patients with ovarian epithelial cancer such as surgery, radiation therapy, and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Epithelial Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 38, 23, 2, 11, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 3 molecules, respectively.Epithelial Ovarian Cancer. Epithelial Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Epithelial Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Epithelial Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Epithelial Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Epithelial Ovarian Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Epithelial Ovarian Cancer Overview 7 Therapeutics Development 8 Epithelial Ovarian Cancer - Therapeutics under Development by Companies 10 Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 15 Epithelial Ovarian Cancer - Pipeline Products Glance 16 Epithelial Ovarian Cancer - Products under Development by Companies 20 Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 26 Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 27 Epithelial Ovarian Cancer - Therapeutics Assessment 94 Drug Profiles 115 Epithelial Ovarian Cancer - Dormant Projects 480 Epithelial Ovarian Cancer - Discontinued Products 484 Epithelial Ovarian Cancer - Product Development Milestones 485 Appendix 495
List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H2 2016 19 Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Number of Products under Development by Companies, H2 2016 (Contd..2) 23 Number of Products under Development by Companies, H2 2016 (Contd..3) 24 Number of Products under Development by Companies, H2 2016 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2016 26 Comparative Analysis by Late Stage Development, H2 2016 27 Comparative Analysis by Clinical Stage Development, H2 2016 28 Comparative Analysis by Early Stage Development, H2 2016 29 Comparative Analysis by Unknown Stage Development, H2 2016 30 Products under Development by Companies, H2 2016 31 Products under Development by Companies, H2 2016 (Contd..1) 32 Products under Development by Companies, H2 2016 (Contd..2) 33 Products under Development by Companies, H2 2016 (Contd..3) 34 Products under Development by Companies, H2 2016 (Contd..4) 35 Products under Development by Companies, H2 2016 (Contd..5) 36 Products under Investigation by Universities/Institutes, H2 2016 37 Epithelial Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016 38 Epithelial Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 39 Epithelial Ovarian Cancer - Pipeline by Amgen Inc, H2 2016 40 Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 41 Epithelial Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016 42 Epithelial Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016 43 Epithelial Ovarian Cancer - Pipeline by Bayer AG, H2 2016 44 Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals Inc, H2 2016 45 Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 46 Epithelial Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016 47 Epithelial Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 48 Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 49 Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp z oo, H2 2016 50 Epithelial Ovarian Cancer - Pipeline by Celsion Corp, H2 2016 51 Epithelial Ovarian Cancer - Pipeline by CerRx Inc, H2 2016 52 Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 53 Epithelial Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016 54 Epithelial Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 55 Epithelial Ovarian Cancer - Pipeline by EirGenix Inc., H2 2016 56 Epithelial Ovarian Cancer - Pipeline by Eisai Co Ltd, H2 2016 57 Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2016 58 Epithelial Ovarian Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 59 Epithelial Ovarian Cancer - Pipeline by Exelixis Inc, H2 2016 60 Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 61 Epithelial Ovarian Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 62 Epithelial Ovarian Cancer - Pipeline by Genentech Inc, H2 2016 63 Epithelial Ovarian Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 64 Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2016 65 Epithelial Ovarian Cancer - Pipeline by Ignyta Inc, H2 2016 66 Epithelial Ovarian Cancer - Pipeline by ImmunoGen Inc, H2 2016 67 Epithelial Ovarian Cancer - Pipeline by Incyte Corp, H2 2016 68 Epithelial Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 69 Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2016 70 Epithelial Ovarian Cancer - Pipeline by Juno Therapeutics Inc, H2 2016 71 Epithelial Ovarian Cancer - Pipeline by Mabion SA, H2 2016 72 Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 73 Epithelial Ovarian Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016 74 Epithelial Ovarian Cancer - Pipeline by MedImmune LLC, H2 2016 75 Epithelial Ovarian Cancer - Pipeline by Merck & Co Inc, H2 2016 76 Epithelial Ovarian Cancer - Pipeline by Merck KGaA, H2 2016 77 Epithelial Ovarian Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 78 Epithelial Ovarian Cancer - Pipeline by Novartis AG, H2 2016 79 Epithelial Ovarian Cancer - Pipeline by Novogen Ltd, H2 2016 80 Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2016 81 Epithelial Ovarian Cancer - Pipeline by OBI Pharma Inc, H2 2016 82 Epithelial Ovarian Cancer - Pipeline by Oncobiologics Inc, H2 2016 83 Epithelial Ovarian Cancer - Pipeline by Oncolix Inc, H2 2016 84 Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 85 Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H2 2016 86 Epithelial Ovarian Cancer - Pipeline by OXIS International, Inc., H2 2016 87 Epithelial Ovarian Cancer - Pipeline by Pharma Mar SA, H2 2016 88 Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd, H2 2016 89 Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2016 90 Epithelial Ovarian Cancer - Pipeline by Rgenix Inc, H2 2016 91 Epithelial Ovarian Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 92 Epithelial Ovarian Cancer - Pipeline by Sanofi, H2 2016 93 Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H2 2016 94 Epithelial Ovarian Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 95 Epithelial Ovarian Cancer - Pipeline by Sotio as, H2 2016 96 Epithelial Ovarian Cancer - Pipeline by TapImmune Inc, H2 2016 97 Epithelial Ovarian Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 98 Epithelial Ovarian Cancer - Pipeline by Tesaro Inc, H2 2016 99 Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016 100 Epithelial Ovarian Cancer - Pipeline by Tyrogenex Inc, H2 2016 101 Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals Inc, H2 2016 102 Epithelial Ovarian Cancer - Pipeline by Verastem Inc, H2 2016 103 Epithelial Ovarian Cancer - Pipeline by Vyriad Inc, H2 2016 104 Assessment by Monotherapy Products, H2 2016 105 Number of Products by Stage and Target, H2 2016 107 Number of Products by Stage and Mechanism of Action, H2 2016 115 Number of Products by Stage and Route of Administration, H2 2016 123 Number of Products by Stage and Molecule Type, H2 2016 125 Epithelial Ovarian Cancer - Dormant Projects, H2 2016 491 Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H2 2016 492 Epithelial Ovarian Cancer - Dormant Projects (Contd..2), H2 2016 493 Epithelial Ovarian Cancer - Dormant Projects (Contd..3), H2 2016 494 Epithelial Ovarian Cancer - Discontinued Products, H2 2016 495
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
